VivoSeq
Other

Finerenone

0

Pipeline Programs↗

1

Active Trials↗

1

Companies Involved↗

Finerenone is an early-stage landscape with 0 programs across 1 company. The most active players are Bayer.

Intelligence

Pipeline Metrics

Competitive Density

6/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Bayer logo

Bayer

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

5

clinical trials

Completed4 · 80%
Not yet recruiting1 · 20%

Clinical Trials

Trial Activity

Study of Finerenone to Investigate a Paediatric Formulation in Healthy Male Volunteers
Completed·Bayer logoBayer·Phase 1·NCT02956109·16 enrolled
Study of Finerenone to Investigate a Paediatric Formulation in Healthy Male Subjects
Completed·Bayer logoBayer·Phase 1·NCT02957396·16 enrolled
A Study to Compare How Much of the Study Treatment Finerenone Gets Into the Blood When the Same Amount is Taken in One and in Two Tablets of Different Strengths in Healthy Male Participants
Completed·Bayer logoBayer·Phase 1·NCT07116512·60 enrolled
Finerenone and Cardiac Remodeling
Not yet recruiting·—·Phase 3·NCT07270367·156 enrolled
A Study to Learn How Finerenone (BAY94-8862) Moves Into, Through and Out of the Body, How it Affects the Body, and How Safe it is in Adult Participants With Different Degrees of Reduced Liver Function and in Healthy Participants With Similar Age, Weight and Gender Distribution
Completed·Bayer logoBayer·Phase 1·NCT04881994·27 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)